Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 9/20 | 0.50 |
| ▸ | THRB | P10828 | 9/20 | 0.50 |
| ▸ | RARB | P10826 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13825789 | 0.86 | CYP4A11 (0.41) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL17071632 | 0.84 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL3683047 | 0.83 | TP53 (0.57) | THRATHRBRARB | |
| SCHEMBL13604062 | 0.82 | THRA (0.48) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL878923 | 0.81 | HPGD (0.52) | THRATHRBMEN1KMT2AALDH1A1 | |
| SCHEMBL7280580 | 0.80 | RARB (0.60) | THRATHRBRARB | |
| SCHEMBL18676418 | 0.79 | THRA (0.38) | THRATHRBMEN1KMT2AALDH1A1 | |
| SCHEMBL11033648 | 0.79 | GSK3A (0.49) | ALDH1A1MAPT | |
| SCHEMBL300884 | 0.79 | CA12 (0.42) | THRBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9743869 | 0.78 | HPGD (0.38) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | THRA 2973/4885THRB 2099/4885RARB 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.